Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutusaus, Anna, Stefanovic, Milica, Boix, Loreto, Cucarull, Blanca, Zamora, Aynara, Blasco, Laura, de Frutos, Pablo García, Reig, Maria, Fernandez-Checa, Jose C., Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908280/
https://www.ncbi.nlm.nih.gov/pubmed/29682179
http://dx.doi.org/10.18632/oncotarget.24673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908280/
https://www.ncbi.nlm.nih.gov/pubmed/29682179
http://dx.doi.org/10.18632/oncotarget.24673

Ejemplares similares